Summary
Investors and analysts said Britain's biggest drugmaker had little obvious need for a transformative acquisition, despite the potential financial benefits.
AstraZeneca’s shares slide 7% after reports of Bristol Myers talks
Source & full coverage: this summary is aggregated from Free Malaysia Today Business, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at Free Malaysia Today Business →
